Phio Pharmaceuticals Corp.
PHIO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PHIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing INTASYL-based RNAi therapeutics for oncology, with a lead candidate PH-762 in early-stage trials and a cash runway of approximately 12 months as of mid-2026.
Key risk: Unproven technology platform
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Phio Pharmaceuticals Corp..
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing INTASYL-based RNAi therapeutics for oncology, with a lead candidate PH-762 in early-stage trials and a cash runway of approximately 12 months as of mid-2026.
- Phio's proprietary INTASYL platform is designed to enable self-delivering RNAi compounds, but the technology is unproven and may never lead to approved products [sec_mda · as of 2026-08-06].
- Lead product candidate PH-762 is in early-stage clinical development, with costs and timelines subject to significant uncertainty [sec_mda · as of 2026-08-06].
- As of June 30, 2026, the company held $13.0 million in cash and equivalents, which management expects to fund operations for at least 12 months [sec_mda · as of 2026-08-06].
- The company reported a net loss of $4.1 million for the quarter ended June 30, 2026, and has an accumulated deficit reflecting years of pre-revenue operations [sec].
- Phio has no approved products and has not generated any product revenue, relying on equity and warrant issuances for financing [sec_mda · as of 2026-08-06].
What works
- Phio's INTASYL platform is a novel self-delivering RNAi technology that could potentially overcome delivery challenges faced by other RNAi therapeutics [sec_mda · as of 2026-08-06].
- The company has sufficient cash to fund its current operating plan for at least 12 months from June 30, 2026, providing a near-term development runway [sec_mda · as of 2026-08-06].
- Phio is advancing PH-762, a clinical-stage candidate targeting solid tumors, with potential for multiple oncology indications [sec_mda · as of 2026-08-06].
What to weigh
- Phio's INTASYL technology and all product candidates are in early-stage development and have not been proven in clinical trials; the company may fail to develop marketable products [sec_mda · as of 2026-08-06].
- The company has no approved products and no product revenue, with a history of net losses and an accumulated deficit [sec_mda · as of 2026-08-06].
- Future capital requirements are uncertain and depend on many factors, including clinical trial results and regulatory outcomes; additional funding may be needed beyond the current cash runway [sec_mda · as of 2026-08-06].
- Phio faces intense competition from other RNAi and oncology therapeutic platforms, which could limit its commercial potential [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
The INTASYL technology is unproven and may never lead to approved products.
“we are dependent on the success of our INTASYLtechnology, and our product candidates based on this technology, which is unproven and may never lead to approved and marketable products”
SEC MD&A · August 6, 2026
Cash and equivalents of $13.0 million as of June 30, 2026, provide at least 12 months of funding.
“At June 30, 2026, we had cash and cash equivalents of $13.0 million. We expect that our cash and cash equivalents will enable us to fund our current operating plan for at least 12 months.”
SEC MD&A · August 6, 2026
PH-762 is in early-stage clinical development with significant uncertainties.
“the scope, progress, results, and costs of nonclinical and clinical trials of PH-762”
SEC MD&A · August 6, 2026
The company has no approved products and relies on financing for operations.
“If we obtain marketing approval for any of our product candidates, we will incur significant sales, marketing and manufacturing expenses.”
SEC MD&A · May 7, 2026
Risks & what to watch (4)›
Key risks
- Unproven technology platform — INTASYL technology is unproven and may never lead to approved products [sec_mda · as of 2026-08-06].
- Early-stage pipeline — All product candidates are in early development; clinical failure is a significant risk [sec_mda · as of 2026-08-06].
- Limited cash runway — Cash of $13.0M as of June 30, 2026, may be insufficient to complete development without additional funding [sec_mda · as of 2026-08-06].
- No product revenue — Company has no approved products and no revenue, relying on equity/debt financing [sec_mda · as of 2026-08-06].
What to watch
- Clinical data updates for PH-762, including any interim or final results from ongoing trials [sec_mda · as of 2026-08-06].
- Cash burn rate and any new financing activities, as the company may need to raise capital beyond the current 12-month runway [sec_mda · as of 2026-08-06].
- Regulatory developments regarding INTASYL platform or PH-762, including any FDA interactions or trial design changes [sec_mda · as of 2026-08-06].
- Progress of pipeline programs such as PH-894, which could expand the company's therapeutic scope [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Phio Pharmaceuticals Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Phio Pharmaceuticals Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
10.0 months
D/E 0.14
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$722K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 159,706 | $195K |
| geode capital management, llc | 147,254 | $180K |
| jane street group, llc | 119,189 | $145K |
| vanguard fiduciary trust co | 38,169 | $47K |
| two sigma investments, lp | 32,495 | $40K |
| xtx topco ltd | 24,868 | $30K |
| northern trust corp | 23,758 | $29K |
| two sigma securities, llc | 15,224 | $19K |
| captrust financial advisors | 10,000 | $12K |
| tower research capital llc (trc) | 7,620 | $9K |
Showing top 10 of 21 institutional holders of Phio Pharmaceuticals Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 4.1%
- Days to cover
- 2.9
- Shares short
- 469,570
- Daily short volume (May 1, 2026)
- 38.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PHIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Phio Pharmaceuticals Corp.?
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing INTASYL-based RNAi therapeutics for oncology, with a lead candidate PH-762 in early-stage trials and a cash runway of approximately 12 months as of mid-2026.
What is Phio Pharmaceuticals Corp.'s lead drug candidate?
Phio Pharmaceuticals Corp.'s most advanced tracked candidate is ph-762 (Phase 1) for Squamous Cell Carcinoma of the Skin.
Who is the CEO of Phio Pharmaceuticals Corp.?
Mr. Robert J. Bitterman is the chief executive officer of Phio Pharmaceuticals Corp. (PHIO).
Where is Phio Pharmaceuticals Corp. headquartered?
Phio Pharmaceuticals Corp. (PHIO) is headquartered in King of Prussia, PA, United States.
What therapeutic areas does Phio Pharmaceuticals Corp. focus on?
Phio Pharmaceuticals Corp. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.